RTP Mobile Logo

Monday, March 18, 2019, Honolulu, Hawaii, 11:00 AM – 12:30 PM

Novel Agents and Emerging Strategies in the Management of Gynecologic Cancers

An Independent CME Satellite Symposium During the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer

Event Details

Location:
Hawaii Convention Center
1801 Kalakaua Ave
Honolulu, HI 96815

Time:
10:30 AM – 11:00 AM — Registration
11:00 AM – 12:30 PM — Educational Lunch Meeting

Meeting Room:
Kalakaua Ballroom A (Level 4)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Faculty:
Michael J Birrer, MD, PhD
Director, O’Neal Comprehensive Cancer Center
Professor of Medicine/Hematology and Oncology
Evalina B Spencer Chair in Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

David M O’Malley, MD
Professor
Medical Director, Gynecologic Oncology
Director, Clinical Research, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
ORIEN Physician Liaison for OSUCCC – James
The Ohio State University and The James Cancer Center
Columbus, Ohio


Matthew Powell, MD
Professor of Obstetrics and Gynecology
Chief, Division of Gynecologic Oncology
Washington University School of Medicine
Saint Louis, Missouri

Additional faculty to be announced


Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Agenda

This CME symposium will focus exclusively on the current and future roles of novel and emerging agents and strategies in the management of ovarian, cervical and endometrial cancer.

Research To Practice president and medical oncologist Dr Neil Love will moderate the program and will be joined by an invited faculty panel of 4 gynecologic oncology investigators. The program will be divided into 4 modules, each featuring the presentation of cases from faculty members’ practices of patients who have received novel and/or investigational agents, panel discussion and a faculty member-led review of related clinical research. To make the program more interactive and relevant, clinician attendees will use iPads® to complete a survey to provide their perspectives on the cases presented and other practical management issues. Survey results will be displayed throughout each module to illuminate any knowledge and practice gaps between the faculty and attending clinicians. Attendees will also be encouraged to use the iPads to submit their own questions and cases to the faculty. Dr Love will incorporate select submissions into the panel discussions to foster additional conversation and ensure that a variety of perspectives emerge.

A detailed agenda will be made available in the coming weeks.

CE Information

Target Audience:
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Review the mechanisms of action, emerging efficacy data and toxicity profiles with novel targeted agents under investigation in ovarian, endometrial and cervical cancer, and effectively prioritize clinical trial opportunities or expanded access programs for eligible patients.
  • Recall the biologic rationale for, published research data with and ongoing research evaluating the use of immune checkpoint inhibitors in the management of ovarian, endometrial and cervical cancer, and identify patients who may be eligible for this strategy in or outside of a protocol setting.
  • Appraise early research data and recently activated clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immune checkpoint inhibitors for gynecologic cancers, and use this information to identify patients who may be eligible for study participation.
  • Recognize the incidence of FRα (folate receptor alpha) overexpression in patients with gynecologic cancers, and consider the potential role of novel agents designed to exploit this therapeutic target.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with novel and recently approved systemic therapies for patients with ovarian, endometrial and cervical cancer to support quality of life and continuation of therapy.
  • Counsel appropriately selected patients with ovarian, endometrial and cervical cancer about participation in ongoing research protocols.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from Eisai Inc, Genmab and Seattle Genetics, ImmunoGen Inc and Tesaro.

Location

Hawaii Convention Center
1801 Kalakaua Ave
Honolulu, HI 96815

Meeting Room:
Kalakaua Ballroom A (Level 4)

Directions:
The Hawaii Convention Center is the main venue for the SGO Annual Meeting on Women’s Cancer.

 

Registration

This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.